Reproducibility of quantitative 18F-3′-deoxy-3′- fluorothymidine measurements using positron emission tomography

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 3, 2009, Pages 389-395

  De Langen, Adrianus J ^a   Klabbers, Bianca ^a   Lubberink, Mark ^a   Boellaard, Ronald ^a   Spreeuwenberg, Marieke D ^a   Slotman, Ben J ^a   De Bree, Remco ^a   Smit, Egbert F ^a   Hoekstra, Otto S ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FLT; Non small cell lung cancer; Positron emission tomography; Reproducibility

Indexed keywords

3' FLUOROTHYMIDINE F 18; ECAT EXACT HR+; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; EVALUATION; HEAD AND NECK TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; PROSPECTIVE STUDY; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 60549104389     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0960-5     Document Type: Article

References (38)

1. Y Yamamoto Y Nishiyama S Ishikawa J Nakano SS Chang S Bandoh 2007 Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 1610 1616
2. EG Troost WV Vogel MA Merkx PJ Slootweg HA Marres WJ Peeters 2007 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients J Nucl Med 48 726 735
3. LM Kenny DM Vigushin A Al-Nahhas S Osman SK Luthra S Shousha 2005 Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods Cancer Res 65 10104 10112
4. H Vesselle J Grierson M Muzi JM Pugsley RA Schmidt P Rabinowitz 2002 In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors Clin Cancer Res 8 3315 3323
5. H Barthel MC Cleij DR Collingridge OC Hutchinson S Osman Q He 2003 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Res 63 3791 3798
6. A Salskov VS Tammisetti J Grierson H Vesselle 2007 FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine Semin Nucl Med 37 429 439
7. H Dittmann BM Dohmen F Paulsen K Eichhorn SM Eschmann M Horger 2003 [18F]FLT PET for diagnosis and staging of thoracic tumours Eur J Nucl Med Mol Imaging 30 1407 1412
8. Y Yamamoto Y Nishiyama N Kimura S Ishikawa M Okuda S Bandoh 2008 Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer Eur J Nucl Med Mol Imaging 35 236 245
9. AK Buck G Halter H Schirrmeister J Kotzerke I Wurziger G Glatting 2003 Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J Nucl Med 44 1426 1431
10. DC Cobben PH Elsinga HJ Hoekstra AJ Suurmeijer W Vaalburg B Maas 2004 Is 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 45 1677 1682
11. AF Shields 2003 PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls J Nucl Med 44 1432 1434
12. AK Buck C Kratochwil G Glatting M Juweid M Bommer D Tepsic 2007 Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT Eur J Nucl Med Mol Imaging 34 1775 1782
13. K Herrmann HA Wieder AK Buck M Schöffel BJ Krause F Fend 2007 Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma Clin Cancer Res 13 3552 3558
14. S Apisarnthanarax MM Alauddin F Mourtada H Ariga U Raju O Mawlawi 2006 Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models Clin Cancer Res 12 4590 4597
15. L Kenny RC Coombes DM Vigushin A Al-Nahhas S Shousha EO Aboagye 2007 Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography Eur J Nucl Med Mol Imaging 34 1339 1347
16. W Chen S Delaloye DH Silverman C Geist J Czernin J Sayre 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 4714 4721
17. B Kasper G Egerer M Gronkowski S Haufe T Lehnert M Eisenhut 2007 Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET Leuk Lymphoma 48 746 753
18. M Perumal RG Pillai H Barthel J Leyton JR Latigo M Forster 2006 Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography Cancer Res 66 8558 8564
19. CJ Hoekstra OS Hoekstra AA Lammertsma 2000 On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies Eur J Nucl Med 27 1579
20. R Boellaard A van Lingen SCM van Balen AA Lammertsma 2004 Optimization of attenuation correction for positron emission tomography studies of thorax and pelvis using count-based transmission scans Phys Med Biol 49 N31 N38
21. R Boellaard A van Lingen AA Lammertsma 2001 Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling J Nucl Med 42 808 817
22. C Riddell RE Carson JA Carrasquillo SK Libutti DN Danforth M Whatley 2001 Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment J Nucl Med 42 1316 1323
23. R Boellaard A van Lingen SC van Balen BG Hoving AA Lammertsma 2001 Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET Eur J Nucl Med 28 81 89
24. CJ Hoekstra OS Hoekstra AA Lammertsma 1999 On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies Eur J Nucl Med 26 1489 1492
25. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; [Epub ahead of print]. doi: 10.1007/s00259-008-0954-3
26. YE Erdi O Mawlawi SM Larson M Imbriaco H Yeung R Finn 1997 Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding Cancer 80 2505 2509
27. AP van der Weerdt LJ Klein R Boellaard CA Visser FC Visser AA Lammertsma 2001 Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans J Nucl Med 42 1622 1629
28. CS Patlak RG Blasberg JD Fenstermacher 1983 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1 7
29. H Akaike 1978 A new look at the statistical identification IEEE Trans Automat Contr 19 716 723
30. G Schwarz 1978 Estimating the dimension of a model Ann Statist 6 461 464
31. CJ Hoekstra I Paglianiti OS Hoekstra EF Smit PE Postmus GJ Teule 2000 Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods Eur J Nucl Med 27 731 743
32. JM Bland DG Altman 1986 Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 307 310
33. M Muzi H Vesselle JR Grierson DA Mankoff RA Schmidt L Peterson 2005 Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer J Nucl Med 46 274 282
34. AF Shields JM Lawhorn-Crews DA Briston KA Douglas TJ Mangner O Muzik 2005 The reproducibility of FLT PET in patients with untreated non-small cell lung cancer J Nucl Med 46 426P
35. B Smyczek-Gargya N Fersis H Dittmann U Vogel G Reischl HJ Machulla 2004 PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study Eur J Nucl Med Mol Imaging 31 720 724
36. LB Been PH Elsinga J de Vries DC Cobben PL Jager HJ Hoekstra 2006 Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT) - a pilot study Eur J Surg Oncol 32 39 43
37. A Dimitrakopoulou-Strauss LG Strauss 2008 The role of 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging 35 523 526
38. M Muzi AM Spence F O'Sullivan DA Mankoff JM Wells JR Grierson 2006 Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas J Nucl Med 47 1612 1621